Heart and liver transplant recipients from donor with positive SARS-CoV-2 RT-PCR at time of transplantation.

coronavirus disease 2019

computed tomography

cycle threshold

real time‐polymerase chain reaction

severe acute respiratory syndrome coronovirus‐2

DISCLOSURE

The authors report no potential conflicts.

AUTHOR CONTRIBUTION

SV and MV designed the study, coordinated the study, collected the data, analyzed and interpreted the results, and wrote the article. PM and EB designed the study, coordinated the study and critically reviewed the article. MS, COB, ZBB, PC, BP, MR, AP, JALB, JH and RA collected the data and critically reviewed the article.

To the editor

At present, there is unclear evidence on the need for a negative severe acute respiratory syndrome coronovirus‐2 (SARS‐CoV‐2) real time‐polymerase chain reaction (RT‐PCR) for donors with a history of COVID‐19 prior to transplantation. , We report two cases of heart and liver transplant recipients from a donor with previous documented COVID‐19 and positive RT‐PCR at time of transplantation.

Donor

A 29‐year‐old woman with confirmed mild COVID‐19 infection 2 months earlier was deceased due to subarachnoid hemorrhage. At time of explanting the organs, the patient had a positive SARS‐CoV‐2 RT‐PCR in a nasopharyngeal swab (Ct 30) and serology with a titer of 954 AU/ml of antispike protein. All these tests were done in another institution. At time of organ extraction, a plasma SARS‐CoV‐2 RT‐PCR was performed in our hospital and it was negative.

Heart recipient

A 66‐year‐old man with a dilated cardiomyopathy was admitted for elective heart transplant. Immunosuppression received was basiliximab, methylprednisolone, tacrolimus, and mycophenolate mofetil. On day +8, the patient developed a severe pericardial effusion requiring drainage. A myocardial biopsy was performed on day +14 revealing no rejection signs. At time of transplantation, the recipient had both negative RT‐PCR and serology for SARS‐CoV‐2. Measurements of SARS‐CoV‐2 RT‐PCR in nasopharyngeal swabs, plasma, and pericardial fluid and serology were done in the subsequent days until day +14 and all of them remained negative (Table 1).

TABLE 1

Microbiological tests of the donor and the two recipients

	Day 0	Day +7	Day +14	Other tests
Donor	NP RT‐PCR SARS‐COV‐2: POS Ct 30 Plasma RT‐PCR SARS‐COV‐2: NEG LB RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2:954 AU/ml			HIV IgG: NEG HBc Ab: NEG HCV IgG: NEG HSV IgG: POS EBV IgG: POS VZV IgG: POS CMV IgG: POS HHV‐6 IgG: NEG TOXO IgG: NEG QFT: NEG
Heart recipient	NP RT‐PCR SARS‐COV‐2: NEG Plasma RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2: NEG	NP RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2: NEG	NP RT‐PCR SARS‐COV‐2: NEG PF RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2: NEG	HIV IgG: NEG HBc Ab: NEG HCV IgG: POS VL HCV: NEG HSV IgG: POS EBV IgG: POS VZV IgG: POS CMV IgG: POS HHV‐6 IgG: NEG TOXO IgG: NEG QFT: NEG
Liver recipient	NP RT‐PCR SARS‐COV‐2: NEG Plasma RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2:26,066 AU/ml	NP RT‐PCR SARS‐COV‐2: NEG LB RT‐PCR SARS‐COV‐2: NEG	NP RT‐PCR SARS‐COV‐2: NEG IgG SARS‐COV‐2:8682 AU/ml	HIV IgG: NEG HBc Ab: NEG HCV IgG: NEG HSV IgG: POS EBV IgG: POS VZV IgG: POS CMV IgG: POS HHV‐6 IgG: POS TOXO IgG: POS QFT: NEG

Abbreviations: LB, liver biopsy; MB, myocardial biopsy; NEG, negative; NP, nasopharyngeal swab; PF, pericardial fluid; POS, positive; QFT, QuantiFERON TB‐Plus™; RT‐PCR, real‐time PCR; TOXO, toxoplasma; VL, viral load.

Liver recipient

A 36‐year‐old man with cirrhosis due to primary biliary cholangitis‐autoimmune hepatitis overlap syndrome was admitted for elective liver transplant. Triple immunosuppression with tacrolimus, mycophenolate mofetil, and corticosteroids were started due to high risk of graft rejection. On day +6 after transplant, an abdominal CT found stenosis at the origin of the left portal vein due to laminar thrombosis and antithrombotic prophylaxis was started. On day +8, a percutaneous liver biopsy reported acute cellular rejection and corticosteroid pulses were prescribed. Before liver transplant, the patient had an asymptomatic COVID‐19 infection. The serology performed at transplantation time revealed a titer of 26,066 AU/mL of antispike protein. Measurements of SARS‐CoV‐2 RT‐PCR in nasopharyngeal swabs, plasma, and hepatic biopsy were performed after transplant and were negative. Titers of antispike protein declined until day +14 but remained positive (Table 1).

In a previous series, 31 kidney transplants were done from COVID‐19 recovered donors whom presented negative SARS‐CoV‐2 RT‐PCR at time of transplantation and recipients did not develop complications related to COVID‐19. , Similarly, nine cases of living liver donors with previous COVID‐19 infection have been reported, but transplantation was delayed until they had two consecutive negative nasopharyngeal RT‐PCR. Unlike kidney transplantation, which could be postponed, heart and liver transplantation have a relative urgency and delays could have a negative impact in the recipients. In our series, the donor had a resolved COVID‐19 infection with a positive RT‐PCR in nasopharyngeal swab at time of transplantation but no donor‐acquired SARS‐CoV‐2 infection occurred. Although guidelines still recommend to avoid using this type of donor in solid organ transplant, having a negative plasma PCR would increase comfort for performing nonlung transplants from donors with recent SARS‐CoV‐2 infection.